The Effect of Beta-glucan in Non-Small Cell Lung Cancer

AIM 2:

Inclusion Criteria:

• suspected or definitive diagnosis of non-small cell lung cancer (NSCLC)

• treatment naive or no treatment within 6 months prior to enrollment

• able to swallow pills

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3

• absolute neutrophil count (ANC) at least 1500/microl

• able to understand and willing to sign a written informed consent document

Exclusion Criteria:

• history of hypersensitivity reactions attributed to beta-glucan

• currently receiving continuous corticosteroids or other ongoing immunosuppressivetherapy

• presence of an uncontrolled intercurrent illness including but not limited to:ongoing or active infection, symptomatic congestive heart failure, unstable anginapectoris, cardiac arrhythmia, or psychiatric illness/social situations that wouldlimit compliance with study requirements

AIM 3:

Inclusion Criteria:

• resectable non-small cell lung cancer (NSCLC), as determined by a thoracic surgeon

• treatment naive

• able to swallow pills

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

• must be an operative candidate

• absolute neutrophil count (ANC) at least 1500/microl

• able to understand and willing to sign a written informed consent document

Exclusion Criteria:

• history of hypersensitivity reactions attributed to beta-glucan

• currently receiving continuous corticosteroids or other ongoing immunosuppressivetherapy

• presence of an uncontrolled intercurrent illness including but not limited to:ongoing or active infection, symptomatic congestive heart failure, unstable anginapectoris, cardiac arrhythmia, or psychiatric illness/social situations that wouldlimit compliance with study requirements